EGFR and lung carcinoma: However, recent advances with targeted therapies, such as epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), have resulted in marked benefit to subsets of lung cancer patients whose tumors have specific genetic mutations.